Xavier Artignan

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy, Jean-François Bosset, Pierre-Luc Etienne et al. · The Lancet Oncology · 2021 · 1.2K citations

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

Thierry Conroy, Najib Lamfichekh, Pierre-Luc Etienne et al. · Journal of Clinical Oncology · 2020 · 177 citations

Surgical Oncology, Cancer Management, Adjuvant Chemotherapy +17

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial

Thierry Conroy, Florence Castan, Pierre-Luc Etienne et al. · Annals of Oncology · 2024 · 144 citations · Full text

Surgical Oncology, Total Neoadjuvant Therapy, Gastrointestinal Oncology +8

Online ultrasound image guidance for radiotherapy of prostate cancer: impact of image acquisition on prostate displacement

Xavier Artignan, Monique H.P. Smitsmans, Jos V Lebesque et al. · International Journal of Radiation Oncology*Biology*Physics · 2004 · 115 citations

Medical Ultrasound, Engineering, Medical Imaging +12

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 111 citations · Full text

Metastatic Breast Cancer, Breast Oncology, Medicine +7